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Corrections 
MEDICAL SCIENCES 
Correction for "Connexin-43 prevents hematopoietic stem cell 
senescence through transfer of reactive oxygen species to bone 
marrow stromal cells," by Eri Taniguchi Ishikawa, Daniel 
Gonzalez-Nieto, Gabriel Ghiaur, Susan K. Dunn, Ashley M. 
Ficker, Bhuvana Murali, Malav Madhu, David E. Gutstein, 
Glenn I. Fishman, Luis C. Barrio, and Jose A. Cancelas, which 
appeared in issue 23, June 5, 2012, of Proc Natl Acad Sci USA 
(109:9071-9076; first published May 18, 2012; 10.1073/pnas. 
1120358109). 
The authors note that both Fig. ÍM and its legend appeared 
incorrectly. The corrected figure and its corresponding legend 
appear below. 
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Fig. 1. H-Cx43 deficiency does not impair serial compet i t i ve repopu la t ion but impairs the hematopo ie t ic recovery af ter 5-FU admin is t ra t ion . (A) Repre-
sentative example of a longi tud ina l section o f p-galactosidase staining of a f emur (or iginal magn i f i ca t ion , 40x) f r o m Vav1-Cre; Rosa-loxP-Stop-loxP-LacZ 
Legend cont inued on f o l l ow ing page 
reporter mice to show presence of recombination in hematopoietic cells. Negative control of BM from non-Cre transgenic littermates is presented (tower). (6 
and C) Genomic recombination of Vav1-Cre;Cx43flox/flox LSK CD34~ BM cells (n = pool of 3 mice per group). (B) Cx43 floxed vs. WT allele PCR. Cx43 floxed band 
is practically abrogated in sorted LSK CD34-. Controls of genomic DNAfrom source animals are also presented for reference. (C) Cx43 floxed-out PCR. (D and 
F) mRNA expression of Cx43 in HSC/P cells isolated from control and H-Cx43-deficient mice (n = pool of 3 mice per group). (D) Semiquantitative RT-PCR for 
Cx43 expression in LSK CD34~ BM cells. (F) Quantitative RT-PCR (Q-RT-PCR) for Cx43 expression in BM MPP. (F) Immunofluorescence pictures showing Cx43 
(green) along with DAPI (blue) in WTor H-Cx43-deficient HSCs. Cx43 is detected around the cell membrane with asymmetric distribution in most of WT HSCs 
(n = 20 HSCs from each individual mouse, n = 3 mice per group). (Scale bar, 5 |im.) (6-/) Serial competitive repopulation assays. Lethally irradiated primary 
recipient CD45.1+ mice were transplanted with a mixture of Vav1-Cre; H-Cx43-deficient BM cells (CD45.2+) and WT BM (CD45.1+) cells (solid circle). Control 
group was transplanted with a mixture of Vav1-Cre; WT BM cells (CD45.2+) and WTBM (CD45.1+) cells (open circle). (6) PB chimera analysis was performed at 
1, 2,3, and 4 mo after transplant in primary recipients. (H) PB chimera of secondary recipients transplanted with 10 x 106 BM cells obtained from primary mice. 
(/) PB chimera of tertiary recipients transplanted with 10 x 106 BM cells obtained from secondary mice. For competitive repopulation assay, 8-16 mice per 
group were transplanted and analyzed from 2 independent experiments. (J and K) PB counts of WT (open circle) or H-Cx43-deficient mice (solid circles) after 
5-FU administration. Counts were performed at the indicated days after 5-FU administration. (_/) Absolute neutrophil counts (ANC). (K) Platelet counts. *P < 
0.05 (n = 3 mice per group in each of two independent experiments). (/.) HSCand MPPcontent of BM on day 21 after 5-FU treatment. (M) Transplant of HSC/P 
cells transduced with a Cx43-expressing lentiviral vector rescues PB recovery after 5-FU administration in H-Cx43-deficient mice. Recipient mice were trans-
planted with LSK BM cells transduced with an empty vector or a Cx43-expressing lentiviral vector. After 4 wk posttransplantation, recipient mice were ad-
ministered 5-FU and PBcell counts and flow cytometric analysis of myeloid (CD11b) recovery were performed at the indicated days after 5-FU administrations. 
• , WTwith empty vector transduction (WT+ Mock); • , WTwith Cx43 transduction (WT + Cx43): Q H-Cx43-def icient with empty vector transduction (H-Cx43-
deficient + Mock); O, H-Cx43-deficient with Cx43 transduction (H-Cx43-deficient + Cx43). *P < 0.05 (n = 4 mice/group in each of two independent experi-
ments). Values represent means ± SD. (W and O) Lethally irradiated primary recipient CD45.1+ mice were transplanted with H-Cx43-deficient BM cells 
(CD45.2+) or Vav1-Cre; WT BM cells (CD45.2+). PB count of WT (open circle) or H-Cx43-def icient mice (solid circle) after 5-FU administration were analyzed after 
4 wk post transplant. (W) Absolute neutrophil count (ANC). (O) Platelet count. *P < 0.05 (n = 5 mice per group). Values represent means ± SD. 
PSYCHOLOGICAL AND COGNITIVE SCIENCES 
Correction for "Exposure therapy triggers lasting reorganization 
of neural fear processing," by Katherina K. Hauner, Susan 
Mineka, Joel L. Voss, and Ken A. Paller, which appeared in issue 
23, June 5, 2012, of Proc Natl Acad Sci USA (109:9203-9208; first 
published May 23, 2012; 10.1073/pnas.l205242109). 
The authors note that the x/y/z coordinates listed for brain 
regions in Table 1 appeared incorrectly. The corrected table 
appears below. This error does not affect the conclusions of 
the article. 
Table 1. Summary of fMRI activity clusters 
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Fig 1. regions shown in blue 
Posterior cingulate (BA 31) 
Anterior cingulate/ vmPFC (BA 24, 32) 
Anterior insula (BA 13) 
Anterior insula (BA 13) 
Posterior insula (BA 13, 19) 
Middle temporal gyrus (BA 39) 
Medial frontal gyrus (BA 6) 
Amygdala (anatomically defined) 
Fig 1. region shown in red 
dIPFC (BA 6, 8) 
Superior parietal lobule (BA 7) 
Fig. 2 regions shown in gray 
Fusiform/lingual gyrus (BA 18, 19) 
Fusiform/lingual gyrus (BA 18, 19) 
For each activity cluster, listed are Brodmann areas (BA), hemisphere [left (L), right (R), or bilateral (B)], the volume (mm3), and stereotactic coordinates for 
the centrally activated voxel (x, y, z mm). Statistics are reported for all P values < 0.10, and otherwise listed as nonsignificant (NSJ. 
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Hematopoietic stem cell (HSC) aging has become a concern in 
chemotherapy of older patients. Humoral and paracrine signals 
from the bone marrow (BM) hematopoietic microenvironment 
(HM) control HSC activity during regenerative hematopoiesis. 
Connexin-43 (Cx43), a connexin constituent of gap junctions 
(GJs) is expressed in HSCs, down-regulated during differentiation, 
and postulated to be a self-renewal gene. Our studies, however, 
reveal that hematopoietic-specific Cx43 deficiency does not result 
in significant long-term competitive repopulation deficiency. In-
stead, hematopoietic Cx43 (H-Cx43) deficiency delays hematopoi-
etic recovery after myeloablation with 5-fluorouracil (5-FU). 5-FU-
treated H-Cx43-deficient HSC and progenitors (HSC/P) cells display 
decreased survival and fail to enter the cell cycle to proliferate. Cell 
cycle quiescence is associated with down-regulation of cyclin D1, 
up-regulation of the cyclin-dependent kinase inhibitors, p21c , p 1 ' 
and p16 I N K 4 a , and Forkhead transcriptional factor 1 (Foxol), and 
activation of p38 mitogen-activated protein kinase (MAPK), indi-
cating that H-Cx43-deficient HSCs are prone to senescence. The 
mechanism of increased senescence in H-Cx43-deficient HSC/P cells 
depends on their inability to transfer reactive oxygen species 
(ROS) to the HM, leading to accumulation of ROS within HSCs. In 
vivo antioxidant administration prevents the defective hemato-
poietic regeneration, as well as exogenous expression of Cx43 in 
HSC/P cells. Furthermore, ROS transfer from HSC/P cells to BM 
stromal cells is also rescued by reexpression of Cx43 in HSC/P. 
Finally, the deficiency of Cx43 in the HM phenocopies the hema-
topoietic defect in vivo. These results indicate that Cx43 exerts 
a protective role and regulates the HSC/P ROS content through 
ROS transfer to the HM, resulting in HSC protection during stress 
hematopoietic regeneration. 
Gja1 | stem cell niche 
Blood cell formation in the bone marrow (BM) is dependent on the close association of developing hematopoietic cells 
with supporting stromal cells. These hematopoietic demands are 
filled by a pool of hematopoietic stem cells (HSCs) with self-
renewal and multipotential differentiation ability. The BM he-
matopoietic microenvironment (HM) has been shown to have 
a crucial role that influences the proliferative activity and dif-
ferentiation process of HSCs and progenitors (HSC/P) by posi-
tive and negative humoral and paracrine signals. 
Gap junctions (GJs) represent a system of direct cell-to-cell 
intercellular communication (IC) (1). Although the existence 
of GJs in BM has been known for over 30 y, their function 
remains unclear (2, 3). GJ channels are formed by dodecamers of 
protein subunits called connexins (Cxs). Cx43 is the predominant 
Cx expressed in the BM, thymus, spleen, and other lymphoid 
tissues (4-6). Cx43 has been shown to be part of the signature 
of HSCs (7-9), being down-regulated during differentiation to 
progenitors (7) and up-regulated in the endosteal space of the 
BM following cytoablative therapy (6). Its deficiency in the BM 
results in deficient hematopoietic regeneration after in vivo 
challenge with 5-fluorouracil (5-FU) (10), which is an established 
stressor of quiescent HSCs (11). However, a mechanistic analysis 
of the role of Cx43 in hematopoietic regeneration has not been 
addressed. In this report, we present compelling data unveiling 
a mechanism of ROS detoxification in HSCs through Cx43-
dependent transfer to the HM that prevents HSC quiescence/ 
senescence after myeloablation. 
Results 
To clarify whether Cx43 plays a crucial role in HSCs and to eluci-
date the mechanism of impaired hematopoietic recovery after 
in vivo 5-FU challenge, we have generated a mouse model with con-
stitutive deficiency of Cx43 in hematopoiesis [Vavl-Cre/Cx43flox/flox, 
hematopoietic specific (H)-Cx43-deficient]. As reported by others 
(12-15), we confirmed that Vavl-Cre expression is extremely effi-
cient, inducing recombination of either a reporter gene (Fig. L4) or 
the floxed Gjal (Cx43flox/flox) gene (Fig. 1 B and C). The mRNA 
expression of Cx43 in HSCs from Vavl-Cre;Cx43flox/flox mice was 
practically abolished in BM HSCs [defined as lineage~/c-kit+/Sca-l+/ 
CD34" (LSK CD34"); Fig. ID] and multipotential progenitors 
(MPPs) (defined as LSK/CD34"1"; Fig. LB). Furthermore, we ana-
lyzed the protein expression of Cx43 in wild-type (WT) and Vavl-
Cre;Cx43f,ox/flox HSCs. Confocal microscopy detected Cx43 protein 
expression in the membrane of isolated HSCs from WT but not 
from Vavl-Cre;Cx43flox/flox mice (Fig. IF). Expression of Cx45 
(Gjcl), another connexin family protein involved in hematopoiesis, 
was detected in both WT and Vavl-Cre;Cx43flox/flox HSCs (Fig. SI) 
and was found not to be significantly up-regulated in H-Cx43-de-
ficient HSCs (Table SI). Cx37 (Gja8) and Cx50 (Gja4) showed 
marginal mRNA expression up-regulation trends (Table SI). Thus, 
the deficiency of Cx43 in HSCs was not associated with significant 
compensatory up-regulation of other connexins. 
To examine whether the loss of Cx43 expression in HSCs 
impairs the BM HSC content and function, we first analyzed 
the peripheral blood (PB) counts (Fig. S24) and content of 
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Fig. 1 . H-Cx43 def ic iency does not impair serial compet i t ive 
repopu la t ion but impairs t he hematopoie t ic recovery af ter 5-FU 
admin is t ra t ion. (A) Representative example of a longitudinal 
section of [S-galactosidase staining of a femur (original m a g n i f i -
ca t i on , 40x) f r o m Vav1-Cre; Rosa-loxP-Stop-loxP-LacZ repor ter 
mice t o show presence o f recombinat ion in hematopo ie t ic eel Is. 
Negat ive cont ro l o f BM f r o m non-Cre transgenic l i t termates is 
presented (Lower). (6 and C) Genomic recombinat ion o f Vav1 -
Cre;Cx43 f l o x / f l o x LSK CD34" BM cells (n = pool o f 3 mice per 
group) . (B) Cx43 f loxed vs. WT allele PCR. Cx43 f loxed band is 
practically abrogated in sorted LSK CD34 - . Controls o f genomic 
DNA f r o m source animals are also presented fo r reference. (C) 
Cx43 f loxed-out PCR. (D and F) mRNA expression o f Cx43 in HSC/ 
P cells isolated f r o m control and H-Cx43-deficient mice (n = pool 
of 3 mice per group) . (D) Semiquant i ta t ive RT-PCR fo r Cx43 
expression in LSK CD34~ BM cells. (F) Quant i ta t ive RT-PCR (Q-
RT-PCR) fo r Cx43 expression in BM MPP. (F) Immunof luores-
cence pictures showing Cx43 (green) a long w i t h DAPI (blue) in 
WT or H-Cx43-deficient HSCs. Cx43 is detected around the cell 
membrane w i t h asymmetric d is t r ibut ion in most of WT HSCs (n 
= 20 HSCs f r o m each indiv idual mouse, n = 3 mice per group) . 
(Scale bar, 5 urn.) (6- / ) Serial compet i t ive repopu la t ion assays. 
Lethally i r radiated pr imary rec ip ient CD45 .1 + mice w e r e 
t ransp lan ted w i t h a mix tu re o f Vav1-Cre; H-Cx43-deficient BM 
cells (CD45.2+) and WT BM (CD45.1+) cells (solid circle). Contro l 
g roup was t ransp lanted w i t h a mix tu re o f Vav1-Cre; WT BM 
cells (CD45.2+) and WT BM (CD45.1+) cells (open circle). (6) PB 
chimera analysis was per fo rmed at 1, 2, 3, and 4 mo af ter 
t ransp lant in pr imary recipients. (H) PB chimera of secondary 
recipients t ransp lanted w i t h 10 x 106 BM cells ob ta ined f r o m 
pr imary mice. (/) PB chimera o f ter t ia ry recipients t ransplanted 
w i t h 10 x 106 BM cells ob ta ined f r o m secondary mice. For 
compet i t i ve repopulat ion assay, 8-16 mice per group were 
t ransplanted and analyzed f r o m 2 independen t exper iments. (J 
and K) PB counts of WT (open circle) or H-Cx43-deficient mice 
(solid circles) a f ter 5-FU admin is t ra t ion . Counts we re per-
f o r m e d at t he indicated days a f ter 5-FU admin is t ra t ion . (_/) 
Abso lu te neu t roph i l counts (ANC). (K) Platelet counts. *P < 
0.05 (n = 3 mice per g roup in each o f t w o independen t 
exper iments). (/.) HSC and MPP conten t o f BM on day 21 a f te r 5-
FU t r ea tmen t . (M) Transplant o f HSC/P cells t ransduced w i t h 
a Cx43-expressing lent iv iral vector rescues PB recovery a f ter 5-
FU admin is t ra t ion in H-Cx43-deficient mice. Recipient mice 
were t ransp lanted w i t h LSKBM cells t ransduced w i t h an emp ty 
vector or a Cx43-expressing lent iv i ra l vector. A f t e r 4 w k post t ransp lan ta t ion , recipient mice we re admin is tered 5-FU and PB cell counts and f l o w cytometr ic 
analysis o f myelo id (CD11 b) recovery were pe r fo rmed at t he indicated days a f ter 5-FU admin is t ra t ions. O, WT w i t h empty vector t ransduct ion (WT + Mock); • , 
WT w i t h Cx43 t ransduct ion (WT + Cx43): Q , H-Cx43-deficient w i t h emp ty vector t ransduct ion (H-Cx43-deficient + Mock); • , H-Cx43-deficient w i t h Cx43 
t ransduct ion (H-Cx43-deficient + Cx43). *P < 0.05 (n = 4 mice/group in each o f t w o independen t exper iments) . Values represent means ± SD. (W and O) 
Lethally i r rad ia ted pr imary recipient CD45.1 + mice we re t ransp lanted w i t h H-Cx43-deficient BM cells (CD45.2+) or Vav1-Cre; WT BM cells (CD45.2+). PB count 
of WT (open circle) or H-Cx43-deficient mice (solid circle) a f ter 5-FU admin is t ra t ion we re analyzed af ter 4 w k post t ransplant . (W) Abso lu te neu t roph i l count 
(ANC). (O) Platelet count . *P < 0.05 (n = 5 mice per g roup) . Values represent means ± SD. 
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phenotypically identifiable BM HSC/P populations. We found 
no significant differences in blood counts or the content of Lin -/ 
c-kit+ (LK), LSK, MPP, or HSC populations in H-Cx43-deficient 
mice (Fig. S25). Second, the HSC content and function were 
assessed in vivo, using serial competitive repopulation assays. 
HSCs from H-Cx43-deficient mice exhibited no significant de-
fect in their competitive engraftment and lineage hematopoiesis 
regeneration (Fig. S3) in the primary (Fig. 1G), secondary (Fig. 
Iff), and tertiary recipient mice (Fig. 17). 
Hematopoietic stress induced by 5-FU has been used to test 
the ability of HSCs to recover homeostatic blood formation 
(16). After a period of pancytopenia, the magnitude of the 
compensatory BM regeneration phase indicates the functional 
reserve of HSCs (17). Repeated administration of 5-FU to mice 
induces exhaustion of the normal HSC pool and a progressive 
inability to recover (18), indicating HSC damage. Similarly to 
mice in which both HSCs and the HM are H-Cx43-deficient (10), 
H-Cx43-deficient mice treated with 5-FU (150 mg/kg i.v.) lack 
a hyperregenerative response phase, as demonstrated by an ab-
rogated rebound in neutrophil (Fig. 17) and platelet (Fig. IK) 
counts in PB, indicating a loss of hematopoietic response activity 
after stress. This deficiency is not persistent because the content 
of HSCs and MPPs in the BM by day 21 after 5-FU challenge 
is similar to WT levels (Fig. IL). The myeloid regeneration of 
H-Cx43-deficient animals after 5-FU administration is completely 
rescued in hematopoietic chimeric mice, where hematopoietic 
Cx43 expression has been reintroduced through transplantation 
of lentivirally transduced LSK cells (Fig. \M). Altogether, there 
results indicate that hematopoietic Cx43 expression is critical for 
hematopoietic regeneration after 5-FU administration. Finally, the 
reduced hematopoietic regeneration of H-Cx43-deficient HSCs 
was confirmed in full chimeras of WT or H-Cx43-deficient BM 
(Fig. 1 N and O), supporting a cell autonomous role of Cx43. 
To examine the underlying cellular mechanism responsible for 
the impaired hematopoietic recovery after 5-FU administration 
in H-Cx43-deficient mice, we analyzed the proliferation status of 
H-Cx43-deficient BM Lin7CD417CD487CD150+ cells, which 
also define phenotypically the HSC population (19, 20) and is 
not affected by down-regulation of c-kit expression during he-
matopoietic regeneration (21) after 5-FU administration. We 
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Fig. 2. H-Cx43-deficient HSCs are impaired to enter cell cycle to proliferate and have decreased cell survival after 5-FU administration. (A) Kinetics of BrdU 
incorporation in HSCs after 5-FU administration. Proliferation of BM-Lin~CD41_CD48~CD150+ cells in WT or H-Cx43-deficient mice was measured by analysis 
of BrdU incorporation at 24, 48, and 96 h after 5-FU administration in vivo. Analysis in WT (open circles) or H-Cx43-deficient (solid circles) mice are presented. 
*P < 0.05 (a minimum of three mice per group in two independent experiments was analyzed). (6) Proliferation of BM-Lin~CD41_CD48~CD150+ cells aftei 
5-FU administration in WT or H-Cx43-deficient mice was measured by analysis of KÍ67 staining in vivo. Analysis in WT (open bars) or H-Cx43-deficien1 
(solid bars) mice are presented. *P < 0.05 (n = 3 mice per group in each of two independent experiments). (C) Pyronin/7-AAD Y cell cycle analysis of WT oi 
H-Cx43-deficient BM after in vivo 5-FU administration. Q, GO phase; hashed box, G1 phase. *P < 0.05 (n = 3 mice per group in each of two independent 
experiments). (D) Q-RT-PCR for p21 and cyclinDI expression in Lin~CD41~CD48~CD150+ BM cells. Analysis in WT (open bars) or H-Cx43-deficient (solid 
bars) mice are presented. *P < 0.05. (F) Frequency of apoptotic (active caspase-3-expressing) cells on HSC and MPP cell populations after 5-FU administration 
in vivo. Data from WT (open bars) or H-Cx43-deficient mice (solid bars) are presented. *P < 0.05. 
first analyzed the frequency of HSCs in DNA synthesis phase 
in vivo at 0, 24, 48, and 96 h after 5-FU administration. Whereas 
WT BM HSCs showed a ^fourfold increase in the frequency of 
HSCs in S phase between days 2 and 4 after 5-FU administration 
(Fig. 24), H-Cx43-deficient HSCs did not significantly cycle, as 
assessed by lack of increase in bromodeoxyuridine (BrdU) up-
take (Fig. 24) or expression of Ki67 (Fig. 25 and Fig. S4>4), by 
96 h after 5-FU administration compared with WT HSCs, which 
confirmed an impaired cell cycle entry in response to chemother-
apeutic stress. Pyronin/7-aminoactinomycin D (7-AAD) staining 
showed accumulation of H-Cx43-deficient HSCs in the G0 phase 
of the cell cycle (Fig. 2C and Fig. S45), indicating that 5-FU 
treated H-Cx43-deficient HSCs also failed to transit through the 
Go/Gx checkpoint. Pathway analysis of the differential tran-
scriptional expression of 5-FU (96 h)-treated H-Cx43-deficient 
HSCs suggested significant impairment of the transition through 
cell cycle checkpoints (Table S2), and Q-RT-PCR confirmed the 
up-regulation of the cyclin dependent kinase p21c l p l and down-
regulation of cyclin Dl mRNA levels in 5-FU (96 h)-treated 
H-Cx43-deficient HSCs (Fig. 2D). In addition, HSCs (and 
MPPs) from H-Cx43-deficient mice showed increased apoptosis 
in vivo (Fig. 2E) and activation of cell death genes (Table S2). 
We next determined the molecular mechanisms associated 
with HSC impaired cell cycle entry in the live gated cell fraction 
of 5-FU-treated H-Cx43-deficient HSCs. We analyzed the ex-
pression and activation through Ser-10 phosphorylation of p53 in 
H-Cx43-deficient HSCs after 5-FU administration, which is as-
sociated with HSC quiescence. We found that H-Cx43-deficient 
HSCs from unchallenged mice expressed a ~2.5-fold higher level 
of activated p53. In 5-FU-treated H-Cx43-deficient HSCs, the 
activation of p53 (Fig. 3^ 4 and Fig. S5) or its downstream targets 
Gadd45a, Pimpl, and Bmil (Fig. 35) were similar to WT HSCs. 
In contrast to p53-dependent HSC quiescence, HSC senescence 
depends on up-regulated expression of the cyclin-dependent ki-
nase inhibitor pl6 NK4a; a hallmark of stem cell aging (22). There 
was a ~twofold increase in the expression of nuclear pl6 I N K 4 a , 
which is up-regulated during cell senescence (22), in both un-
challenged and in vivo 5-FU-challenged H-Cx43-deficient HSCs 
(Fig. 3C). In addition, there was a ~twofold up-regulation of the 
expression of Rbl, a central regulator of the Gx phase of the cell 
cycle and a regulator of interactions between HSCs and the HM 
(Table S2) (23). These results indicate that the H-Cx43-deficient 
HSCs are prone to senescence under stress. 
A major pathway of pl6 up-regulation in HSC senescence is 
ROS-dependent activation of p38 (24). Pathway analysis of 
the top signaling pathways differentially expressed by 5-FU-
treated H-Cx43-deficient HSCs showed a statistically significant 
activation of oxidative damage in 5-FU-treated HSCs from 
H-Cx43-deficient mice (Table S2). Analysis of the intracellular 
levels of ROS (H 2 0 2 and Oz") in WT and H-Cx43-deficient 
HSCs after 5-FU administration, showed that H-Cx43-deficicient 
HSCs after 5-FU administration had an ~1.8- to 2.1-fold in-
crease in intracellular ROS content compared with WT HSCs 
(Fig. 3 D and E). The production of ROS is one of the 
byproducts of mitochondrial respiration, and mitochondrias have 
frequently been considered as the main source of cellular-
Fig. 3. Cell cycle arrest in H-Cx43-deficient after 5-FU treatment is associated 
with increased levels of intracellular ROS and activation of quiescence markers 
p16 and p38. (A) Immunofluorescence intensity of anti-phopho-p53 immu-
nostaining of BM-Lin~CD41~CD48~CD150+ cells from WT (open bars) or H-
Cx43-deficient mice (solid bars) after 5-FU administration was measured by 
using computer-imaging software (Axiovision; Zeiss). *P< 0.05 (n = 20-35 cells 
per group were measured from a minimum of two mice per group). (6) Q-RT-
PCR of p53 downstream targets in BM-Lin~CD41~CD48~CD150+ cells, isolated 
from WT (open bars) and H-Cx43-deficient mice (solid bars) after 5-FU ad-
ministration. (C) Immunofluorescence intensity of anti-p16 immunostaining 
of BM-Lin~CD41~CD48~CD150+ cells from WT (open bars) or H-Cx43-def icient 
mice (solid bars) after 5-FU administration. *P < 0.05 (n = 20-35 cells per group 
were measured from a minimum of 2 mice per group). (D-F) Intracellular H202 
level measured with DCF-DA (D), intracellular 02~ level measured with DHE (F) 
and mitochondrial-derived superoxide levels (F) in BM-Lin~CD4TCD48~CD150+ 
cells from WT (open bars) or H-Cx43-deficient mice (solid bars) after 5-FU ad-
ministration. *P < 0.05 (n = 3 mice per group in each of two independent 
experiments). (6 and H) Mitochondrial size (MitoTracker Green FM) (6) and mi-
tochondrial potential (MitoTrackerRed FM) (hi) of BM-Lin~CD41~CD48~CD150+ 
cells after 5-FU administration in WT (open bars) or H-Cx43-deficient mice (solid 
bars) were measured in vivo. *P < 0.05 (n = 3 mice per group). (/ and J) Mean 
fluorescent intensity of phospho-p38 (/) and phospho-MAPK (_/) of BM-
Lin~CD41~CD48~CD150+ cells from WT (open bars) or H-Cx43-deficient mice 
(solid bars) after 5-FU administration. *P<0.05 (n = 3 mice per group in each of 
two independent experiments). (K) Q-RT-PCR for Foxol expression in BM-
Lin~CD41~CD48~CD150+ cells, isolated from WT (open bars) and H-Cx43-de-
f icient mice (solid bars) after 5-FU administration *P < 0.05 (pool of three mice 
per group). Values represent means ± SD. 
derived ROS (25). Mitochondrial Cx43 has been shown to play 
a role in mediating the cardioprotective effect of ischemic pre-
conditioning through modification of the mitochondrial content 
and membrane potential (26). Analysis of Ü2 - generated by 
mitochondrial activity showed that, similarly to overall intra-
cellular ROS levels, mitochondrial-derived superoxide levels 
were increased in 5-FU-treated H-Cx43-deficient HSCs com-
pared with WT HSCs (Fig. 3F). However, the mitochondrial 
mass was not affected and the mitochondrial membrane poten-
tial only marginally decreased in unchallenged H-Cx43-deficient 
HSCs but not after 5-FU administration (Fig. 3 G and H), in-
dicating that the deficiency of Cx43 does not correlate with sig-
nificant modifications in mitochondrial mass or membrane 
potential. Moreover, increased ROS levels correlated with in-
creased p38 activation (Fig. 37) but not extracellular signal-reg-
ulated kinase (Erk) activation (Fig. 3/). Activation of p38 
correlated with Foxol expression (Fig. 3K), which, in addition 
to pl6 I N K 4 a up-regulation, have been shown to be hallmarks of 
ROS-dependent HSC repopulation loss-of-function (24) and 
HSC resistance to physiologic oxidative stress (27), respectively. 
Transfer of small molecules is arguably a well-recognized 
function of Cx43-dependent channels (28). We hypothesized 
that Cx43 deficiency would lead to accumulated levels of in-
tracellular ROS in HSCs, resulting in cell cycle arrest, apoptosis, 
and senescence. To test this hypothesis, we performed a set of 
mechanistic experiments to address the role of Cx43 in the 
control of HSC ROS content. First, we tested whether antioxi-
dant therapy with JV-acetyl-L-cysteine (NAC), a reducing agent 
that diminishes the endogenous level of intracellular ROS, could 
reverse the impaired hematopoietic regeneration of H-Cx43-
deficient mice after 5-FU administration. WT or H-Cx43-de-
ficient animals were treated daily with NAC or control vehicle 
starting 1 d before 5-FU administration. There was a complete 
restoration of the neutrophil and platelet count recovery in 
H-Cx43-deficient mice after in vivo treatment with NAC to the 
levels seen in WT mice treated with PBS or NAC (ANOVA; P < 
0.05 for both neutrophil and platelet counts) (Fig. 4 A and B). 
These data prove that oxidative stress is causal in the hemato-
poietic recovery delay of H-Cx43-deficient HSCs after 5-FU 
administration. 
Second, it has been shown that Cx43 mediates BM stromal cell 
adhesion to HSCs (29). To address whether the contact of HSCs 
with BM stromal cells was causal in the control of HSC ROS 
levels, we cocultured HSC/P cells derived from WT or H-Cx43-
deficient mice with preplated FBMD-1 stromal cells, a well-
recognized model of heterocellular hematopoiesis-supporting 
stroma (30) composed of ROShlgh and ROS low cell populations 
(Fig. S6). We then analyzed whether ROS could be efficiently 
transferred from WT HSC/P cells to BM stromal cells. Before 
culture, primary sorted HSC/P cells were treated with LY83583 
(6-anilino-5,8-quinolinequinone), a generator of superoxide 
anions (31), to model increased ROS production as seen in vivo 
after 5-FU administration; and BM stromal cells were treated 
with NAC, to diminish basal ROS levels. The intracellular con-
centration of ROS in HSC/P cells was measured in sorted HSC/P 
cells by flow cytometric analysis of fluorescence intensity of dihy-
droethidium (DHE), an 02~ reporter that binds to DNA irre-
versibly upon oxidation becoming unavailable to be transferred 
through GJs. When HSC/P cells were plated without FBMD-1 
stroma as a control, LY83583-treated WT or H-Cx43-deficient 
HSC/P cells showed high intracellular ROS levels (Fig. AC). 
When WT HSC/P cells were cultured onto FBMD-1 cells, 
however, the intracellular ROS levels in WT HSC/P cells di-
minished significantly (~83% reduction; P < 0.001) compared 
with H-Cx43-deficient HSC/P cells (Fig. AC). Although FBMD-1 
cells maintained their ability to reduce ROS content of H-Cx43-
deficient HSC/P cells (-64% reduction; P = 0.02), they did so 
to a lesser degree (P = 0.03) than in WT HSC/P, indicating that 
the ability of FBMD-1 cells to diminish ROS concentration in 
HSC/P cells is lessened by the Cx43 deficiency in HSC/P cells. 
Third, if ROS transfer is the mechanism of ROS scavenging, 
then culture of high ROS-containing HSC/P cells onto FBMD-1 
cells should increase the intracellular levels of ROS in the 
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Fig. 4. Antioxidant therapy reverses the impaired hematopoietic regeneration 
after 5-FU in H-Cx43-def icient mice and HSOP Cx43 is required for ROS transfer 
to BM stromal cells. (A and 6) In vivo NAC treatment restored PB recovery 
after 5-FU administration in H-Cx43-deficient mice. (A) Absolute neutrophil 
count (ANC). (B) Platelet count. O, WT + PBS; • , WT + NAC; Q H-Cx43-
deficient + PBS; • , H-Cx43-deficient + NAC. *P < 0.05, n = 3 mice per group. 
(Cand D) ROS transfer from HSOP cells into FBMD-1 stromal cells. Diagram 
of the coculture method (Upper). Green cells represent sorted LSK cells. 
Red areas represent nuclei containing the ROS reporter DHE. Orange arrows 
represent expected directional transfer of ROS. (C-F) Cx43 mediates ROS 
depletion from HSCs and uptake by BM stromal cells. (C) CFSE/DHE double-
labeled HSC/P cells isolated from WT or H-Cx43-deficient mice were seeded 
onto FBMD-1 stromal cells for 3 h. Before coculture, sorted HSC/P cells were 
treated with LY83583 to induce ROS production, and FBMD-1 cells were 
treated with NAC for 16 h. Median fluorescent intensity of DHE in CFSE+ 
HSC/P cells was measured by flow cytometry. (D) CFSE-labeled, sorted HSC/P 
cells from WT or H-Cx43-deficient mice were cultured with preformed DHE-
labeled FBMD-1 stroma for 3 h. Before loading, HSC/P cells were treated with 
LY83583 to induce ROS and FBMD-1 cells had been treated with NAC for 
16 h. MFI of DHE in FBMD-1 cells was measured by FACS. MFI of FBMD-1 cells 
preincubated or not with NAC was also analyzed. *P < 0.05, **P < 0.01. Data 
represent three independent experiments. (F) Sorted HSC/P cells from WT 
or H-Cx43-deficient mice were transduced with an empty vector or a Cx43-
expressing lentiviral vector and cultured with preformed DHE-labeled FBMD-
1 stroma for 3 h. Before loading, HSC/P cells were treated with LY83583 
to induce ROS and FBMD-1 cells had been treated with NAC for 16 h. MFI 
of DHE in FBMD-1 cells was measured by FACS. **P < 0.05; *P < 0.1. Data 
represent two independent experiments. Empty bar, WT with empty vector 
transduction; black bar, H-Cx43-deficient with empty vector transduction; 
pink bar, WT with Cx43 transduction; red bar, H-Cx43-deficient with Cx43 
transduction. Values represent means ± SD. (F) Neutrophil count of WT HM 
chimeric mice (open circles) and H-Cx43-deficient HM chimeric mice (solid 
circles) after 5-FU administration. *P < 0.05 (n = 3 mice per group). (6 and H) 
BM cell and progenitor (CFU-C) content in two femurs, two tibia, and pelvis 
of WT HM (empty bars) and H-Cx43-deficient HM (solid bars) chimeric mice 
on day 11 postadministration of 5-FU. *P < 0.05 (n = 3 mice per group). 
Values represent means ± SD. 
stromal cells. As a control, we checked that overnight NAC 
treatment of FBMD-1 cells significantly reduces the intracellular 
ROS levels (Fig. AD). A 3-h coculture of WT HSC/P cells onto 
FBMD-1 reversed the effect of NAC, returning intracellular 
ROS levels similar to those in untreated FBMD-1 cells (Fig. AD). 
However, H-Cx43-deficient HSC/P cells were unable to increase 
the transfer of ROS to FBMD-1 cells beyond the basal levels of 
NAC-treated FBMD-1 cells (Fig. AD). Furthermore, exogenous 
expression of WT Cx43 in lentivirally transduced Cx43-deficient 
HSCs rescued the decreased transfer of ROS into the stromal 
cells in H-Cx43-deficient HSC/P cells to the same level of WT-
Mock HSC/P cells (Fig. AE and Fig. S6). Together, these data 
indicate that Cx43 mediates the transfer of ROS from HSC/P 
cells to hematopoiesis-supporting BM stromal cells. 
Finally, to address whether Cx43 homotypic interactions be-
tween HSCs and BM stroma were at play, we analyzed whether 
Cx43 deficiency in the HM phenocopies the deficiency of Cx43 in 
the HSC compartment with respect to its inability to regenerate 
stress hematopoiesis. For this purpose, we induced Cx43 de-
ficiency in the HM (10) using Mxl-Cre transgenic mice as shown 
previously (23, 32). Mxl-Cre;WT and Mxl-Cre;Cx43flox/flox mice 
were treated with polyinositide;polycytidine (polyLC). One week 
after the last injection of polyLC, the mice were submitted to 
lethal irradiation, followed by transplantation of WT CD45.1+ 
BM. Chimeric mice (>90% CD45.1+ hematopoietic chimera) 
were challenged with 5-FU in the same way as in primary Vavl-
Cre;Cx43flox/fi°x mice. The myeloid regeneration of HM Cx43-
deficient mice phenocopied the defective regeneration observed 
in H-Cx43-deficient mice, as assessed by neutrophil counts in the 
PB (Fig. AF) and reduced BM cellularity and progenitor content 
(Fig. 4 G and H). This suggests that Cx43 expression in the HM 
is similarly required for hematopoietic regeneration and Cx43-
Cx43 heterologous interactions between HSC/P cells and the 
cellular HM are required for an adequate regenerative response 
after chemotherapy. 
Discussion 
HSCs are responsible for sustaining blood formation and re-
generation after injury for the entire lifespan of an organism 
through self-renewal, survival, proliferation, and differentiation. 
HSC aging has become a concern in chemotherapy of older 
patients. HSC function declines with age, and prolonged mye-
losuppression in response to cytotoxic chemotherapy drugs sug-
gests a reduced marrow regenerative capacity in older individuals 
(33-36). However, the number of HSCs does not necessarily 
decline, but it can also increase (37, 38). There is evidence to 
indicate a distinct role for intrinsic and extrinsic factors in HSC 
aging to explain this apparent discrepancy (39). However, the 
molecular mechanisms that regulate the HM control on HSC 
function during aging are poorly understood. 
HSC functions can be affected by the intracellular level of ROS 
that are produced endogenously through cellular metabolism or 
directly after exposure to exogenous stress, and ROS levels have 
long been associated with aging (40). At physiological levels, low 
and moderate levels of ROS appear to be required for HSC ac-
tivity (41^-3), including early hematopoietic reconstitution after 
transplantation (44). However, a sustained, abnormal increase in 
ROS production occurs under aging (24) and genotoxic stress 
(45), including 5-FU chemotherapy (46), which can inhibit HSC 
self-renewal and induce HSC senescence and hematopoietic dys-
function (24). Mimicking the situation in aged individuals, the 
HSC BM content of H-Cx43-deficient old mice is increased over 
aged-matched controls (47), whereas their ability to regenerate 
after 5-FU administration is diminished (Ref. 10 and Fig. 1 / and 
K). Followed by 5-FU administration, HSCs from H-Cx43-de-
ficient mice showed decreased ability to enter the cell cycle and 
survive, as well as an increased intracellular ROS content. 
In this report, we demonstrate a function of the HM as 
a scavenger of ROS from stressed HSC/P cells through Cx43. 
Our data provide evidence that Cx43 deficiency cannot be sig-
nificantly compensated by other connexins, at either expression 
or functional levels, and Cx43 is a major mediator of ROS 
scavenging through transfer from HSCs to stromal cells. 
It has been shown that ROS can regulate HSC function in 
a concentration-dependent manner. High levels of ROS can in-
duce HSC senescence and apoptosis secondary to DNA damage 
(24). Whereas Cx43 deficiency induces increased apoptosis, 
surviving HSCs from H-Cx43-deficient mice display the hall-
marks of senescence, including hyporegenerative capacity and 
cell cycle arrest after chemotherapy, and up-regulation of pl6 INK4a. 
Hyporegenerative/senescent HSCs are induced by high levels of 
ROS/p38MAPK/Foxol signal activation, and HSC loss-of-func-
tion can be reverted by NAC administration in vivo or by the 
reintroduction of Cx43, indicating that Cx43 is a crucial molecule 
in the maintenance of HSC fitness. The reintroduction of Cx43 
also rescues the ROS transfer from ROShigh HSC/P cells to BM 
stromal cells, confirming the expected role of HSC Cx43 in ROS 
scavenging by the HM. Finally, the deficiency of Cx43 in the HM 
in chimeric mice generated by transplanting WT hematopoiesis 
(>90%) into an inducible murine model of Cx43 deficiency (10) 
significantly phenocopies the deficiency of Cx43 in HSCs. 
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